Cargando…
Gut microbiota and pro/prebiotics in Alzheimer’s disease
Alzheimer’s disease is characterized by the accumulation of amyloid and dysfunctional tau protein in the brain along with the final development of dementia. Accumulation of amyloid in the brain was observed 10-20 years before the onset of clinical symptoms by diagnostic methods based on image analys...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138569/ https://www.ncbi.nlm.nih.gov/pubmed/32191919 http://dx.doi.org/10.18632/aging.102930 |
_version_ | 1783518597104009216 |
---|---|
author | Pluta, Ryszard Ułamek-Kozioł, Marzena Januszewski, Sławomir Czuczwar, Stanisław J. |
author_facet | Pluta, Ryszard Ułamek-Kozioł, Marzena Januszewski, Sławomir Czuczwar, Stanisław J. |
author_sort | Pluta, Ryszard |
collection | PubMed |
description | Alzheimer’s disease is characterized by the accumulation of amyloid and dysfunctional tau protein in the brain along with the final development of dementia. Accumulation of amyloid in the brain was observed 10-20 years before the onset of clinical symptoms by diagnostic methods based on image analysis. This is a serious public health problem, incidence and prevalence being expected to reach epidemic proportions over the next few decades if the disease cannot be prevented or slowed down. Recently, in addition to the strongly developing ischemic etiology of Alzheimer’s disease, it is suggested that the gut microbiota may also participate in the development of this disease. The brain and gut are thought to form a network called the “gut-brain-microbiota axis”, and it is strongly supported idea that the intestinal microflora can be involved in Alzheimer’s disease. Lately, many new studies have been conducted that draw attention to the relationship between Alzheimer’s disease and gut microbiota. This review presents a possible relationship between Alzheimer’s disease and a microbiome. It is a promising idea for prevention or therapeutic intervention. Modulation of the gut microbiota through a personalized diet or beneficial microflora intervention like pro/prebiotics, changing microbiological partners and their products, including amyloid protein, can become a new treatment for Alzheimer’s disease. |
format | Online Article Text |
id | pubmed-7138569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Impact Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-71385692020-04-13 Gut microbiota and pro/prebiotics in Alzheimer’s disease Pluta, Ryszard Ułamek-Kozioł, Marzena Januszewski, Sławomir Czuczwar, Stanisław J. Aging (Albany NY) Review Alzheimer’s disease is characterized by the accumulation of amyloid and dysfunctional tau protein in the brain along with the final development of dementia. Accumulation of amyloid in the brain was observed 10-20 years before the onset of clinical symptoms by diagnostic methods based on image analysis. This is a serious public health problem, incidence and prevalence being expected to reach epidemic proportions over the next few decades if the disease cannot be prevented or slowed down. Recently, in addition to the strongly developing ischemic etiology of Alzheimer’s disease, it is suggested that the gut microbiota may also participate in the development of this disease. The brain and gut are thought to form a network called the “gut-brain-microbiota axis”, and it is strongly supported idea that the intestinal microflora can be involved in Alzheimer’s disease. Lately, many new studies have been conducted that draw attention to the relationship between Alzheimer’s disease and gut microbiota. This review presents a possible relationship between Alzheimer’s disease and a microbiome. It is a promising idea for prevention or therapeutic intervention. Modulation of the gut microbiota through a personalized diet or beneficial microflora intervention like pro/prebiotics, changing microbiological partners and their products, including amyloid protein, can become a new treatment for Alzheimer’s disease. Impact Journals 2020-03-19 /pmc/articles/PMC7138569/ /pubmed/32191919 http://dx.doi.org/10.18632/aging.102930 Text en Copyright © 2020 Pluta et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Pluta, Ryszard Ułamek-Kozioł, Marzena Januszewski, Sławomir Czuczwar, Stanisław J. Gut microbiota and pro/prebiotics in Alzheimer’s disease |
title | Gut microbiota and pro/prebiotics in Alzheimer’s disease |
title_full | Gut microbiota and pro/prebiotics in Alzheimer’s disease |
title_fullStr | Gut microbiota and pro/prebiotics in Alzheimer’s disease |
title_full_unstemmed | Gut microbiota and pro/prebiotics in Alzheimer’s disease |
title_short | Gut microbiota and pro/prebiotics in Alzheimer’s disease |
title_sort | gut microbiota and pro/prebiotics in alzheimer’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138569/ https://www.ncbi.nlm.nih.gov/pubmed/32191919 http://dx.doi.org/10.18632/aging.102930 |
work_keys_str_mv | AT plutaryszard gutmicrobiotaandproprebioticsinalzheimersdisease AT ułamekkoziołmarzena gutmicrobiotaandproprebioticsinalzheimersdisease AT januszewskisławomir gutmicrobiotaandproprebioticsinalzheimersdisease AT czuczwarstanisławj gutmicrobiotaandproprebioticsinalzheimersdisease |